# XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Canonical URL: https://biopharmsignal.com/news/XOMA/xoma-royalty-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-18-2026
Ticker: XOMA
Company: XOMA Corporation
Source: XOMA Corporation
Published: 2026-03-12 10:30 EST
Original Source URL: https://investors.xoma.com
## Summary

<p>EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the resu

## Article Body
EMERYVILLE, Calif., March  12, 2026  (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the results and provide a business update.

The webcast will be accessible on the “News & Events” page in the Investors section of XOMA Royalty’s website (www.investors.xoma.com/news-events). A replay of the webcast will be available for 30 days following the live event.

About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

Investor contact: 
Media contact:

Juliane Snowden
Kathy Vincent

XOMA Royalty Corporation
KV Consulting & Management

+1-646-438-9754
kathy@kathyvincent.com

juliane.snowden@xoma.com

Source: XOMA Royalty Corporation
## Recent Company News
- 2026-07-14 13:00 EST — [XOMA Royalty Announces Closing of Its Acquisition by Ligand](https://biopharmsignal.com/news/XOMA/xoma-royalty-announces-closing-of-its-acquisition-by-ligand-6ca7a63d) — Source: XOMA Corporation
- 2026-06-12 20:05 EST — [XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date](https://biopharmsignal.com/news/XOMA/xoma-royalty-corporation-declares-quarterly-preferred-stock-dividend-and-announc-b8285e5a) — Source: XOMA Corporation
- 2026-04-27 11:00 EST — [Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator](https://biopharmsignal.com/news/XOMA/ligand-to-acquire-xoma-royalty-further-accelerating-profit-growth-and-strengthening-ligand-s-position-as-a-leading-biopharma-royalty-aggregator) — Source: XOMA Corporation
- 2026-03-18 20:30 EST — [XOMA Royalty Declares Quarterly Preferred Stock Dividends](https://biopharmsignal.com/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-dividends) — Source: XOMA Corporation
- 2026-03-18 10:00 EST — [XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements](https://biopharmsignal.com/news/XOMA/xoma-royalty-reports-2025-financial-results-and-highlights-recent-business-achievements) — Source: XOMA Corporation
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)